Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

1. Swain, S.M.
2. Kim, S.-B.
3. Cortés, J.
4. Ro, J.
5. Semiglazov, V.
6. Campone, M.
7. Ciruelos, E.
8. Ferrero, J.-M.
9. Schneeweiss, A.
10. Knott, A.
11. Clark, E.
12. Ross, G.
13. Benyunes, M.C.
14. Baselga, J.